EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges

Attila A Seyhan iD

International Journal of Molecular Sciences · 21.07.2024 · 25 (14) · 7974

DOI: 10.3390/ijms25147974 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 21.07.2024. Verfasst von Attila A Seyhan. Beteiligte Einrichtung: Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA. Hauptthemen laut MEDLINE: Glioblastoma, Biomarkers, Tumor, Neoplastic Cells, Circulating, Brain Neoplasms. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 363 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gliomas, particularly glioblastoma (GBM), represent the most prevalent and aggressive tumors of the central nervous system (CNS). Despite recent treatment advancements, patient survival rates remain low. The diagnosis of GBM traditionally relies on neuroimaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scans and postoperative confirmation via histopathological and molecular analysis. Imaging techniques struggle to differentiate between tumor progression and treatment-related changes, leading to potential misinterpretation and treatment delays. Similarly, tissue biopsies, while informative, are invasive and not suitable for monitoring ongoing treatments. These challenges have led to the emergence of liquid biopsy, particularly through blood samples, as a promising alternative for GBM diagnosis and monitoring. Presently, blood and cerebrospinal fluid (CSF) sampling offers a minimally invasive means of obtaining tumor-related information to guide therapy. The idea that blood or any biofluid tests can be used to screen many cancer types has huge potential. Tumors release various components into the bloodstream or other biofluids, including cell-free nucleic acids such as microRNAs (miRNAs), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), proteins, extracellular vesicles (EVs) or exosomes, metabolites, and other factors. These factors have been shown to cross the blood-brain barrier (BBB), presenting an opportunity for the minimally invasive monitoring of GBM as well as for the real-time assessment of distinct genetic, epigenetic, transcriptomic, proteomic, and metabolomic changes associated with brain tumors. Despite their potential, the clinical utility of liquid biopsy-based circulating biomarkers is somewhat constrained by limitations such as the absence of standardized methodologies for blood or CSF collection, analyte extraction, analysis methods, and small cohort sizes. Additionally, tissue biopsies offer more precise insights into tumor morphology and the microenvironment. Therefore, the objective of a liquid biopsy should be to complement and enhance the diagnostic accuracy and monitoring of GBM patients by providing additional information alongside traditional tissue biopsies. Moreover, utilizing a combination of diverse biomarker types may enhance clinical effectiveness compared to solely relying on one biomarker category, potentially improving diagnostic sensitivity and specificity and addressing some of the existing limitations associated with liquid biomarkers for GBM. This review presents an overview of the latest research on circulating biomarkers found in GBM blood or CSF samples, discusses their potential as diagnostic, predictive, and prognostic indicators, and discusses associated challenges and future perspectives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBiomarkers, TumorNeoplastic Cells, CirculatingBrain NeoplasmsHumansLiquid BiopsyCirculating Tumor DNA

Stichwörter der Autor:innen

biomarkerscell-free DNA (cfDNA)circulating microRNAs (miRNAs)circulating tumor DNA (ctDNA)circulating tumor cells (CTCs)diagnosisextracellular vesicles (EVs) and exosomesglioblastomametabolomicsprognosisproteomics

Substanzen

Biomarkers, TumorCirculating Tumor DNA

Autor:innen und Institutionen

  • Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.
  • Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02912, USA.
  • Joint Program in Cancer Biology, Lifespan Health System and Brown University, Providence, RI 02912, USA.
  • Legorreta Cancer Center, Brown University, Providence, RI 02912, USA.

ORCID-Profile: Attila A Seyhan

Zitieren

APA

Seyhan, A. A. (2024). Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges. International Journal of Molecular Sciences, 25(14), 7974. https://doi.org/10.3390/ijms25147974

Vancouver

Seyhan AA. Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges. International Journal of Molecular Sciences. 2024;25(14):7974. doi:10.3390/ijms25147974

BibTeX
@article{Seyhan2024,
  author = {Seyhan, Attila A},
  title = {Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {14},
  pages = {7974},
  doi = {10.3390/ijms25147974}
}
Kostenlos starten →